الفهرس 
COVEROnly 14 pages are availabe for public view
 |  | from | 140 |  |  |
| | | from | 140 | | |
Abstract
Background: The pathogenesis and the impact of therapy onthrombin activation in children with acute lymphoblastic leukemia(ALL) are unknown. Steroids may contribute to ALL-associatedthrombosis.
Objectives:The aim of this study isto assess children with newly diagnosed ALL for Von Willebrand Factor antigen and Factor VIII relevant to peripheral blast cells and the effect of steroids therapy on their levels.
Patients and Methods: This study was conducted on 32 newly diagnosed patients ALL patients; 24 patients with peripheral blasts, and 8 patients without peripheral blasts.
Results:The study showed that at diagnosis patients with peripheral blasts had a significantly higher levels of VWF antigen (P<0.001), FVIII (P=0.001), and total leucocytic count (P=0.008) than those without peripheral blasts.
After 8 days of steroid therapy, patients with peripheral blasts had a significant reduction in both VWF antigen (P<0.001) and FVIII (P=0.003). While those without peripheral blasts showed a significant increase in VWF antigen (P<0.001) and FVIII (P<0.001). Patients with peripheral blasts had a significant decrease in total leucocytic count (P=0.03), and no change in platelet, hemoglobin levels than those without peripheral blasts.
There was no significant correlation between VWF antigen, FVIII levels and hemoglobin, platelets levels at diagnosis and after 8 days of steroid therapy.
There was a significant positive correlation between total leucocytic count and VWF antigen (P=0.001),and between peripheral blasts and VWF antigen (P<0.001), FVIII (P=0.002) at diagnosis among acute lymphoblastic leukemia patients with peripheral blasts.
Conclusion: Elevation of VWF antigen and in parallel to it FVIII at diagnosis of ALL with high peripheral blood blast cell count.
Correlation of VWF and FVIII to each other and to peripheral blood blast cell count.
Effect of 8-day steroid therapy on DROP of TLC, blast cell count and both VWF and FVIII in patients with high peripheral blood cell count.